All In Biotech

Drug Trial Radar · NCT07684898

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

A Single-Arm, Open-Label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Therapy in Patients With Severe Hemophilia A (Adults and Adolescents)

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Mar 9, 2027

Study completion Jun 21, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The indication for this product is to control and prophylaxis in patients with Hemophilia A (congenital Factor VIII deficiency): The Primary Objective: To evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated patients with severe Hemophilia A. Secondary Objectives: To evaluate the health-related quality of life, pharmacokinetic (PK) profiles, safety and immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated subjects with severe Hemophilia A.

Conditions

  • Severe Hemophilia A

Interventions

  • FRSW107Drug

    For subjects in the PK subgroup: they will receive a dose of 50 IU/kg at the first dose visit 1 to obtain preliminary pharmacokinetic (PK) data. After assessment by the investigator, individualized prophylactic treatment (25\~50 IU/kg, Q3D) will be administered to maintain the trough concentration of FVIII activity at ≥1%. For subjects not in the PK subgroup: they will receive prophylactic treatment at a dose of 25\~50 IU/kg once every three days. If a subject experiences a breakthrough bleeding episode requiring treatment, the investigator shall determine the appropriate dosage (recommended dose range: 20\~50 IU/kg) and administration frequency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ABRTime frame: 6 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Fuyang Hospital, Affiliated to Anhui Medical University

    Fuyang, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, China

  • Anhui Provincial Hospital

    Hefei, China

  • Jinan central hospital

    Jinan, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, China

  • Qinghai Provincial People's Hospital

    Qinghai, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, China

  • Wenzhou People's Hospital

    Wenzhou, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.

    Wuhan, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, China

  • Xi'an Central Hospital

    Xi'an, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Zhengzhou People's Hospital

    Zhengzhou, China

  • Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.